HER2 Deficient Expression is an inclusion criterion in 875 clinical trials for breast carcinoma, of which 593 are open and 282 are closed. Of the trials that contain HER2 Deficient Expression and breast carcinoma as inclusion criteria, 17 are early phase 1 (11 open), 266 are phase 1 (167 open), 149 are phase 1/phase 2 (105 open), 324 are phase 2 (218 open), 9 are phase 2/phase 3 (7 open), 83 are phase 3 (66 open), 6 are phase 4 (2 open), and 21 are no phase specified (17 open) [5].

Everolimus, exemestane, alpelisib, fulvestrant, pembrolizumab, letrozole, ribociclib, palbociclib, tamoxifen, abemaciclib, aromatase inhibitor, atezolizumab, nab-paclitaxel, anastrozole, and sacituzumab govitecan have evidence of efficacy in patients with HER2 Deficient Expression in breast carcinoma [5].

HER2 Deficient Expression is an inclusion criterion in 147 clinical trials for malignant solid tumor, of which 100 are open and 47 are closed. Of the trials that contain HER2 Deficient Expression and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open), 101 are phase 1 (64 open), 37 are phase 1/phase 2 (28 open), and 8 are phase 2 (7 open) [5].

HER2 Deficient Expression is an inclusion criterion in 112 clinical trials for non-small cell lung carcinoma, of which 74 are open and 38 are closed. Of the trials that contain HER2 Deficient Expression and non-small cell lung carcinoma as inclusion criteria, 66 are phase 1 (39 open), 29 are phase 1/phase 2 (21 open), 16 are phase 2 (13 open), and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 90 clinical trials for ovarian carcinoma, of which 57 are open and 33 are closed. Of the trials that contain HER2 Deficient Expression and ovarian carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 54 are phase 1 (27 open), 24 are phase 1/phase 2 (20 open), 10 are phase 2 (8 open), and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 66 clinical trials for invasive breast carcinoma, of which 60 are open and 6 are closed. Of the trials that contain HER2 Deficient Expression and invasive breast carcinoma as inclusion criteria, 2 are early phase 1 (2 open), 9 are phase 1 (7 open), 2 are phase 1/phase 2 (1 open), 43 are phase 2 (40 open), 1 is phase 2/phase 3 (1 open), 8 are phase 3 (8 open), and 1 is no phase specified (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 64 clinical trials for colorectal carcinoma, of which 43 are open and 21 are closed. Of the trials that contain HER2 Deficient Expression and colorectal carcinoma as inclusion criteria, 40 are phase 1 (26 open), 17 are phase 1/phase 2 (13 open), 6 are phase 2 (3 open), and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 56 clinical trials for gastric carcinoma, of which 34 are open and 22 are closed. Of the trials that contain HER2 Deficient Expression and gastric carcinoma as inclusion criteria, 30 are phase 1 (15 open), 14 are phase 1/phase 2 (11 open), 9 are phase 2 (6 open), and 3 are phase 3 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 56 clinical trials for head and neck squamous cell carcinoma, of which 40 are open and 16 are closed. Of the trials that contain HER2 Deficient Expression and head and neck squamous cell carcinoma as inclusion criteria, 34 are phase 1 (22 open), 17 are phase 1/phase 2 (14 open), 4 are phase 2 (3 open), and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 52 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 37 are open and 15 are closed. Of the trials that contain HER2 Deficient Expression and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 22 are phase 1 (14 open), 9 are phase 1/phase 2 (7 open), 10 are phase 2 (8 open), 1 is phase 2/phase 3 (1 open), 9 are phase 3 (7 open), and 1 is no phase specified (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 47 clinical trials for breast adenocarcinoma, of which 44 are open and 3 are closed. Of the trials that contain HER2 Deficient Expression and breast adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open), 12 are phase 1 (12 open), 5 are phase 1/phase 2 (4 open), 14 are phase 2 (13 open), 11 are phase 3 (10 open), and 4 are no phase specified (4 open) [5].

HER2 Deficient Expression is an inclusion criterion in 46 clinical trials for melanoma, of which 29 are open and 17 are closed. Of the trials that contain HER2 Deficient Expression and melanoma as inclusion criteria, 1 is early phase 1 (0 open), 25 are phase 1 (15 open), 9 are phase 1/phase 2 (7 open), 10 are phase 2 (6 open), and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 40 clinical trials for gastric adenocarcinoma, of which 31 are open and 9 are closed. Of the trials that contain HER2 Deficient Expression and gastric adenocarcinoma as inclusion criteria, 14 are phase 1 (10 open), 8 are phase 1/phase 2 (7 open), 9 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), 7 are phase 3 (6 open), and 1 is no phase specified (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 37 clinical trials for fallopian tube carcinoma, of which 24 are open and 13 are closed. Of the trials that contain HER2 Deficient Expression and fallopian tube carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 25 are phase 1 (13 open), 7 are phase 1/phase 2 (6 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 37 clinical trials for urothelial carcinoma, of which 26 are open and 11 are closed. Of the trials that contain HER2 Deficient Expression and urothelial carcinoma as inclusion criteria, 20 are phase 1 (12 open), 13 are phase 1/phase 2 (10 open), and 4 are phase 2 (4 open) [5].

HER2 Deficient Expression is an inclusion criterion in 36 clinical trials for renal cell carcinoma, of which 23 are open and 13 are closed. Of the trials that contain HER2 Deficient Expression and renal cell carcinoma as inclusion criteria, 19 are phase 1 (9 open), 10 are phase 1/phase 2 (8 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 35 clinical trials for primary peritoneal carcinoma, of which 22 are open and 13 are closed. Of the trials that contain HER2 Deficient Expression and primary peritoneal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 23 are phase 1 (11 open), 7 are phase 1/phase 2 (6 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 35 clinical trials for small cell lung carcinoma, of which 26 are open and 9 are closed. Of the trials that contain HER2 Deficient Expression and small cell lung carcinoma as inclusion criteria, 16 are phase 1 (10 open), 14 are phase 1/phase 2 (11 open), and 5 are phase 2 (5 open) [5].

HER2 Deficient Expression is an inclusion criterion in 33 clinical trials for endometrial carcinoma, of which 27 are open and 6 are closed. Of the trials that contain HER2 Deficient Expression and endometrial carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 19 are phase 1 (16 open), 12 are phase 1/phase 2 (9 open), and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 33 clinical trials for pancreatic carcinoma, of which 23 are open and 10 are closed. Of the trials that contain HER2 Deficient Expression and pancreatic carcinoma as inclusion criteria, 20 are phase 1 (12 open), 11 are phase 1/phase 2 (9 open), and 2 are phase 2 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 30 clinical trials for prostate carcinoma, of which 20 are open and 10 are closed. Of the trials that contain HER2 Deficient Expression and prostate carcinoma as inclusion criteria, 19 are phase 1 (10 open), 8 are phase 1/phase 2 (7 open), and 3 are phase 2 (3 open) [5].

HER2 Deficient Expression is an inclusion criterion in 29 clinical trials for esophageal carcinoma, of which 17 are open and 12 are closed. Of the trials that contain HER2 Deficient Expression and esophageal carcinoma as inclusion criteria, 11 are phase 1 (4 open), 11 are phase 1/phase 2 (9 open), 5 are phase 2 (3 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 28 clinical trials for cervical carcinoma, of which 24 are open and 4 are closed. Of the trials that contain HER2 Deficient Expression and cervical carcinoma as inclusion criteria, 19 are phase 1 (16 open), 7 are phase 1/phase 2 (6 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 25 clinical trials for hepatocellular carcinoma, of which 20 are open and 5 are closed. Of the trials that contain HER2 Deficient Expression and hepatocellular carcinoma as inclusion criteria, 14 are phase 1 (10 open), 9 are phase 1/phase 2 (8 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 24 clinical trials for bladder carcinoma, of which 14 are open and 10 are closed. Of the trials that contain HER2 Deficient Expression and bladder carcinoma as inclusion criteria, 16 are phase 1 (7 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (3 open), and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 16 clinical trials for pancreatic adenocarcinoma, of which 10 are open and 6 are closed. Of the trials that contain HER2 Deficient Expression and pancreatic adenocarcinoma as inclusion criteria, 10 are phase 1 (7 open), 5 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 13 clinical trials for lymphoma, of which 6 are open and 7 are closed. Of the trials that contain HER2 Deficient Expression and lymphoma as inclusion criteria, 9 are phase 1 (4 open) and 4 are phase 1/phase 2 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 13 clinical trials for soft tissue sarcoma, of which 7 are open and 6 are closed. Of the trials that contain HER2 Deficient Expression and soft tissue sarcoma as inclusion criteria, 8 are phase 1 (2 open) and 5 are phase 1/phase 2 (5 open) [5].

HER2 Deficient Expression is an inclusion criterion in 12 clinical trials for esophageal adenocarcinoma, of which 12 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and esophageal adenocarcinoma as inclusion criteria, 4 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), and 2 are phase 3 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 12 clinical trials for head and neck carcinoma, of which 8 are open and 4 are closed. Of the trials that contain HER2 Deficient Expression and head and neck carcinoma as inclusion criteria, 9 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 11 clinical trials for squamous cell lung carcinoma, of which 8 are open and 3 are closed. Of the trials that contain HER2 Deficient Expression and squamous cell lung carcinoma as inclusion criteria, 7 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 10 clinical trials for pancreatic ductal adenocarcinoma, of which 6 are open and 4 are closed. Of the trials that contain HER2 Deficient Expression and pancreatic ductal adenocarcinoma as inclusion criteria, 7 are phase 1 (6 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 9 clinical trials for breast invasive ductal carcinoma, of which 8 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and breast invasive ductal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), 2 are phase 3 (2 open), and 2 are no phase specified (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 9 clinical trials for glioblastoma, of which 5 are open and 4 are closed. Of the trials that contain HER2 Deficient Expression and glioblastoma as inclusion criteria, 6 are phase 1 (4 open), 2 are phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 9 clinical trials for mesothelioma, of which 6 are open and 3 are closed. Of the trials that contain HER2 Deficient Expression and mesothelioma as inclusion criteria, 9 are phase 1 (6 open) [5].

HER2 Deficient Expression is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and prostate adenocarcinoma as inclusion criteria, 5 are phase 1 (5 open) and 4 are phase 1/phase 2 (3 open) [5].

HER2 Deficient Expression is an inclusion criterion in 8 clinical trials for colorectal adenocarcinoma, of which 7 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and colorectal adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open), 4 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 8 clinical trials for ductal carcinoma in situ, of which 7 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and ductal carcinoma in situ as inclusion criteria, 1 is phase 1 (1 open), 5 are phase 2 (4 open), and 2 are no phase specified (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 8 clinical trials for high grade ovarian serous adenocarcinoma, of which 7 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and high grade ovarian serous adenocarcinoma as inclusion criteria, 7 are phase 1 (6 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 8 clinical trials for Merkel cell carcinoma, of which 7 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and Merkel cell carcinoma as inclusion criteria, 2 are phase 1 (1 open), 4 are phase 1/phase 2 (4 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 7 clinical trials for inflammatory breast carcinoma, of which 6 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and inflammatory breast carcinoma as inclusion criteria, 7 are phase 2 (6 open) [5].

HER2 Deficient Expression is an inclusion criterion in 7 clinical trials for sarcoma, of which 4 are open and 3 are closed. Of the trials that contain HER2 Deficient Expression and sarcoma as inclusion criteria, 4 are phase 1 (2 open) and 3 are phase 1/phase 2 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 6 clinical trials for cholangiocarcinoma, of which 4 are open and 2 are closed. Of the trials that contain HER2 Deficient Expression and cholangiocarcinoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 6 clinical trials for clear cell renal cell carcinoma, of which 4 are open and 2 are closed. Of the trials that contain HER2 Deficient Expression and clear cell renal cell carcinoma as inclusion criteria, 5 are phase 1 (3 open) and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 6 clinical trials for esophageal squamous cell carcinoma, of which 6 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and esophageal squamous cell carcinoma as inclusion criteria, 4 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 6 clinical trials for esophagogastric carcinoma, of which 5 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and esophagogastric carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 6 clinical trials for nasopharyngeal carcinoma, of which 5 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and nasopharyngeal carcinoma as inclusion criteria, 5 are phase 1 (4 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 6 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and non-hodgkin lymphoma as inclusion criteria, 6 are phase 1 (6 open) [5].

HER2 Deficient Expression is an inclusion criterion in 6 clinical trials for skin squamous cell carcinoma, of which 6 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and skin squamous cell carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 3 are phase 1/phase 2 (3 open) [5].

HER2 Deficient Expression is an inclusion criterion in 5 clinical trials for acute myeloid leukemia, of which 4 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 5 clinical trials for breast invasive lobular carcinoma, of which 5 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and breast invasive lobular carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 5 clinical trials for cancer, of which 2 are open and 3 are closed. Of the trials that contain HER2 Deficient Expression and cancer as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 5 clinical trials for malignant ovarian epithelial tumor, of which 5 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and malignant ovarian epithelial tumor as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 4 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 5 clinical trials for peritoneal mesothelioma, of which 2 are open and 3 are closed. Of the trials that contain HER2 Deficient Expression and peritoneal mesothelioma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 4 clinical trials for biliary tract carcinoma, of which 4 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and biliary tract carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 2 are closed. Of the trials that contain HER2 Deficient Expression and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 4 clinical trials for cutaneous melanoma, of which 4 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and cutaneous melanoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 2 are closed. Of the trials that contain HER2 Deficient Expression and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 4 clinical trials for lung adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and lung adenocarcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 4 clinical trials for multiple myeloma, of which 3 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 4 clinical trials for non-squamous non-small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for adenoid cystic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and adenoid cystic carcinoma as inclusion criteria, 3 are phase 1 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for bilateral breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and bilateral breast carcinoma as inclusion criteria, 3 are phase 2 (3 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for breast lobular carcinoma in situ, of which 3 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and breast lobular carcinoma in situ as inclusion criteria, 2 are phase 2 (2 open) and 1 is no phase specified (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for colon carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and colon carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for gallbladder carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and gallbladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for intrahepatic cholangiocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for malignant pleural mesothelioma, of which 3 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and malignant pleural mesothelioma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for malignant uterine neoplasm, of which 3 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and malignant uterine neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for mantle cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain HER2 Deficient Expression and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for pleural mesothelioma, of which 0 are open and 3 are closed. Of the trials that contain HER2 Deficient Expression and pleural mesothelioma as inclusion criteria, 3 are phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 3 clinical trials for thymic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and thymic carcinoma as inclusion criteria, 3 are phase 1 (3 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 1 is open and 1 is closed. Of the trials that contain HER2 Deficient Expression and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for anal canal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for anal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and anal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain HER2 Deficient Expression and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for cervical squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and cervical squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for classical hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for endometrial endometrioid adenocarcinoma, of which 0 are open and 2 are closed. Of the trials that contain HER2 Deficient Expression and endometrial endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for extrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and extrahepatic cholangiocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain HER2 Deficient Expression and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 1 is open and 1 is closed. Of the trials that contain HER2 Deficient Expression and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for hematopoietic and lymphoid malignancy, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for hypopharyngeal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and hypopharyngeal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for laryngeal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and laryngeal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for lobular breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and lobular breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for malignant ovarian clear cell tumor, of which 1 is open and 1 is closed. Of the trials that contain HER2 Deficient Expression and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for medullary breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and medullary breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for mixed lobular and ductal breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and mixed lobular and ductal breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 1 is open and 1 is closed. Of the trials that contain HER2 Deficient Expression and myelodysplastic syndromes as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for neuroendocrine carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HER2 Deficient Expression and neuroendocrine carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for oropharyngeal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and oropharyngeal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for ovarian endometrioid adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain HER2 Deficient Expression and ovarian endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for primary peritoneal serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for small intestinal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain HER2 Deficient Expression and small intestinal adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for thymoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and thymoma as inclusion criteria, 2 are phase 1 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and thyroid gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 2 clinical trials for vulvar carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 Deficient Expression and vulvar carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for adnexal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and adnexal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for anal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and anal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for appendix adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and appendix adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for B-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and B-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for basal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and basal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for benign breast neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and benign breast neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for cervical carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and cervical carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and chordoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and double-hit lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and endometrial adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for endometrial mixed adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and endometrial mixed adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for gastric diffuse adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and gastric diffuse adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for hypopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and hypopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for invasive papillary breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and invasive papillary breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for Kaposi sarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and Kaposi sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for kidney carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and kidney carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for laryngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and laryngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and leiomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for leukemia, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and leukemia as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant colorectal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and malignant colorectal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant digestive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and malignant digestive system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant endometrial neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and malignant endometrial neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant exocrine pancreatic neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and malignant exocrine pancreatic neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant mixed mesodermal (mullerian) tumor, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and malignant mixed mesodermal (mullerian) tumor as inclusion criteria, 1 is early phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant ovarian neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and malignant ovarian neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant urethral neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and malignant urethral neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for malignant uterine corpus neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and malignant uterine corpus neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for mucinous breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and mucinous breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for myxofibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and myxofibrosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for NUT midline carcinoma of the head and neck, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and NUT midline carcinoma of the head and neck as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for ovarian carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and ovarian carcinosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and ovarian endometrioid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine neoplasm, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and pancreatic neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and penile carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for peritoneal malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and peritoneal malignant mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for pleural biphasic mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and pleural biphasic mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for pleural epithelioid mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and pleural epithelioid mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for pleural mesothelioma, sarcomatoid type, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and pleural mesothelioma, sarcomatoid type as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for primary peritoneal carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and primary peritoneal carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for prostate undifferentiated carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and prostate undifferentiated carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for pseudomyxoma peritonei, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and pseudomyxoma peritonei as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for renal pelvis and ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and renal pelvis and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for salivary gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and salivary gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for tenosynovial giant cell tumor, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and tenosynovial giant cell tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for tenosynovial giant cell tumor, diffuse type, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and tenosynovial giant cell tumor, diffuse type as inclusion criteria, 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 Deficient Expression and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for transformed non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for tubular breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and tubular breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for urethral carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and urethral carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and vaginal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HER2 Deficient Expression is an inclusion criterion in 1 clinical trial for well-differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 Deficient Expression and well-differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].